Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients

Coronavirus disease 2019 (COVID-19) is a global pandemic that has caused more than 600 million cases and over six million deaths worldwide. Despite the availability of vaccination, COVID-19 cases continue to grow making pharmacological interventions essential. Remdesivir (RDV) is an FDA-approved ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Kaiyan, Stern, Sydney, Heil, Emily L., Li, Linhao, Khairi, Rula, Heyward, Scott, Wang, Hongbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949788/
https://www.ncbi.nlm.nih.gov/pubmed/36809346
http://dx.doi.org/10.1097/HC9.0000000000000034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949788/
https://www.ncbi.nlm.nih.gov/pubmed/36809346
http://dx.doi.org/10.1097/HC9.0000000000000034

Ejemplares similares